Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03148535
Other study ID # 2016-1-4111
Secondary ID
Status Recruiting
Phase Phase 4
First received May 9, 2017
Last updated May 9, 2017
Start date June 1, 2017
Est. completion date December 1, 2018

Study information

Verified date May 2017
Source Peking University
Contact Ji-Tao Li, MD
Phone 010-62723742
Email ljt_102124@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The bipolar depression patients of 18-55 years old were recruited. At the time of enrollment, the demographic, symptomatic, neuropsychological, neurobiological and genetic data was collected. After the completion of the baseline assessment and examination, the patients were given lithium carbonate or lithium carbonate combined with SSRI antidepressant treatment. Clinical evaluation was performed at 2 and 8 weeks after treatment, including the therapeutic efficacy and adverse drug reactions, and monitoring of serum lithium concentration. The patients further receive the fMRI scans after treatment for 8 weeks. Through above work, this study aimed to provide some guidance for the use of antidepressants in patients with bipolar depression.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date December 1, 2018
Est. primary completion date December 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- age 18-55 years old, bipolar depression

Exclusion Criteria:

- other mental illness, serious somatic illnesses, MRI contradictions.

Study Design


Related Conditions & MeSH terms

  • Bipolar Disorder
  • the Use of Antidepressants in Patients With Bipolar Depression

Intervention

Drug:
Lithium Carbonate
bipolar depression recieve lithium Carbonate treatment
lithium carbonate combined with SSRI antidepressant treatment
lithium carbonate combined with SSRI antidepressant treatment

Locations

Country Name City State
China Institute of mental health, Peking University Beijing Beijing
China Dalian No.7 People's Hospital Dalian Liaoning
China Nanjing Brain Hospital Nanjing Jiangsu
China The first hospital of Hebei Province University Shijiazhuang Hebei

Sponsors (1)

Lead Sponsor Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary HRSD reduction ratio HRSD reduction ratio 8 weeks